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Abstract
Background: Pituitary adenomas as multifactorial intracranial neoplasms impose a massive burden of morbidity on
patients and characterizing the molecular mechanism underlying their pathogenesis has received considerable
attention. Despite the appealing role of cyclooxygenase enzymes and their bioactive lipid products in cancer
pathogenesis, their relevance to pituitary adenoma pathogenesis is debated and yet to be determined. Thus, the
current study perused this relevance.
Methods: The expression level of the isoforms of cyclooxygenase (COX-1 and COX-2) was evaluated in hormone-
secreting and in-active pituitary adenoma tumors and normal pituitary tissues through Real-Time PCR. The level of
PGE2, as the main product of enzymes, was assessed using enzyme immunoassay kits in patients and healthy
subjects.
Results: The results of the current study demonstrated that COX-1 and COX-2 expression levels were increased in
pituitary tumors including non-functional pituitary adenoma (NFPA), acromegaly, Cushing’s disease and
prolactinoma compared with normal pituitary tissues. A significant expression level of COX-2 was observed in NFPA
compared with the other pituitary tumors. Furthermore, the COX-2 expression level was significantly increased in
macroadenoma and invasive tumors. The level of PGE2 was consistent with COX enzymes enhanced in pituitary
adenoma tumors compared with healthy pituitary tissue. A significant elevation in the PGE2 level was detected in
NFPA compared with hormone-secreting pituitary tumors. Additionally, the PGE2 level was increased in
macroadenoma compared with microadenoma and in invasive compared with non-invasive pituitary tumors. The
diagnostic values of cyclooxygenase isoforms and PGE2 were considerable between patients and healthy groups;
however, COX-2 revealed more value in distinguishing endocrinologically active and non-active pituitary tumors.
Conclusions: Data from the current study provides expression patterns of COX-1, COX-2 and PGE2 in prevalent
pituitary tumors and their association with patients’ clinical features which may open up new molecular targets for
early diagnosis/follow up of pituitary tumor growth.
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Background
The molecular mechanism by which tumor cells are grown,
proliferated, developed and metastasized is under extensive
investigation. The inter-tumor heterogeneity [1], micro-
environment of tumor cells [2], presence of cancer-stem
cell populations [3] and inflammatory mediators [4] are the
most recently determined cellular events by which tumor
cell fate is influenced. Among the molecular pathways re-
lated to inflammation, the enzymes of the prostaglandin
pathway are well characterized as inflammatory mediators
which are implicated in the pathogenesis of cancer and
other diseases [5, 6]. Cyclooxygenases are the peroxidases
responsible for converting arachidonic acid to prostaglan-
dins that can be released from cells and activated specified
receptors, triggering cellular signaling pathways mediating
fever, vasodilation, platelet aggregation, pain and inflamma-
tion [4, 7, 8]. The constitutively expressed cyclooxygenase
isoform, the so-called cycloxygensae-1 (COX-1) is located
in chromosome 9 and is involved in cell proliferation,
angiogenesis and tissue hemostasis [7]. The inducible iso-
form of cyclooxygenase, namely- cyclooxygenase-2 (COX-
2), is located in chromosome 1 and stimulated by growth
factors and cytokines and contributed in inflammatory re-
sponses [9]. The overexpression of COX-2 has been re-
ported in several types of tumors, including breast,
pancreatic, lung, colorectal, leukemia and lymphoma tu-
mors [4]. Accumulated evidences has revealed that COX-2
is involved in tumor cell proliferation [10], invasion [11],
angiogenesis [12], apoptosis [13], drug resistance [14] and
immune evasion [15]. The prostaglandin E2 (PGE2) as the
main product of COX-2 mediates its effects in cancer cell
proliferation, invasion and death through activation of the
PGE2 receptor (EP) and subsequent induction of cAMP
and protein kinase K [16]. Additionally, PGE2 is able to
suppress apoptosis by attenuating the level of pro-apoptotic
mediators in colorectal cancer [17]. Activation of the Src
kinase and the subsequent phosphorylation of STAT3,
which positively regulates cell cycle effectors, are supposed
to be mediated by PGE2 in lung cancer [18]. Also, the pro-
moting impact of PGE2 on VEGF expression emphasizes
its role in angiogenesis and facilitation of tumor invasion
[19–21]. Despite the fact that COX isoforms share struc-
tural and enzymatic similarities, different regulatory ap-
proaches, tissue distribution and the subsequent activities
are believed to affect their role in cell function [7]. The ac-
curate role of COX-1 in cancer pathogenesis is debated and
less considered, while elevated levels of COX-1 have been
detected in some types of cancers. Accordingly, the over-
expression of COX-1 has been correlated with the poor
prognosis of renal cell carcinoma [22]. The up-regulation of
COX-1 has been revealed in the cytoplasm of neoplastic
cells in head and neck cancer [23]. It seems that both iso-
forms influence cancer pathogenesis coordinately; however,
this premise should be verified with further evidences. The
pituitary gland function is linked to the normal physiology
of the human body and tightly related to the metabolism,
reproduction, stress controlling and immune responses.
The dynamic adjustment of pituitary gland cells to meet
the hormonal requirement of the body during growth and
maturation makes this master gland more appealing [24].
The heterogeneous group of tumors arises from the pituit-
ary gland which accounts for approximately 20% of intra-
cranial neoplasms. Pituitary adenomas are classified mainly
based on their ability to change hormonal level, tumor size
and invasiveness [25]. As hormone-secreting pituitary aden-
omas, prolactinoma (excess of prolactin), Cushing’s disease
(excess of ACTH) and acromegaly (excess of growth hor-
mone) are the most prevalent types, although non-
functional pituitary adenomas which lack hormone overpro-
duction, affect a large number of patients worldwide, and
their diagnosis is more challenging [26]. Characterization of
the pathophysiology of pituitary adenomas might pave the
way for the early diagnosis and follow up of pituitary aden-
omas. Despite few observations regarding the over expres-
sion of COX-2 in pituitary carcinomas, the expression
patterns of both COX isoforms and PGE2 in different types
of pituitary adenomas and their correlations with tumor
types, size and behavior have yet to be determined; thus,
they were considered and investigated in the current study.
Methods
Patients and sample collection
The total number of 91 pituitary samples including 71 pi-
tuitary adenomas and 20 cadaveric healthy pituitary tis-
sues were enrolled in the current study with local ethical
approval and informed consent which was ethically ap-
proved by the ethics committee of vice president of re-
search in Iran University of Medical Sciences. The tumor
and normal pituitary sample collection was followed as
the method of Barooni et al. [27]. Notably, to avoid the
possible effect of pituitary adenomas medical treatments
on the COX expression and PGE2 level assessment, only
the patients who received no treatments prior to surgery
were selected and enrolled in this study. The clinic- patho-
logical features of patients with pituitary adenoma are
summarized in Table 1. Additionally, invasive pituitary tu-
mors were classified in terms of the Knosp classification
system in which tumor extension to the adjacent sphenoid
sinus and cavernous sinus is defined as invasive tumor.
Also, in our study the tumor tissues greater than 10mm
in size were considered as macroadenomas and tumors
less than 10mm in size were defined as microadenomas.
The patient’s biochemical features and their hormone
levels were assessed and summarized in Table 2.
RNA extraction, cDNA synthesis, real-time PCR
The expression levels of COX isoforms were measured
using specific primers via Real-Time PCR based on the
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methods and materials described previously [27]. The se-
quence and characters of primers are listed in Table 3. The
beta-actin expression level, as a housekeeping target gene,
was measured to normalize the COX isoforms expression
level. The beta-actin is considered as a housekeeping gene
with the most constant level in the brain and pituitary tis-
sues. To evaluate the accuracy of beta-actin, the serial dilu-
tion of cDNA at the concentrations of 0.01, 0.1, 1, 10, and
100 ng / μl were prepared, and the standard curve was
constructed with the logarithm of the initial copy number
of the standards plotted along with the x-axis, and their re-
spective CT values were plotted along with the y-axis. The
low CT values as well as the standard efficiency confirmed
the beta-actin as a suitable housekeeping gene for our assay.
ELISA measurement of PGE2 level
The level of PGE2 as a main product of COX isoforms
was assessed in tissue homogenates of tumor and normal
Table 2 The biochemical features of patients with pituitary adenoma
Demographic features NFPA Acromegaly Cushing Prolactinoma
Age 55.12 ± 5.12 45.23 ± 3.2 35.7 ± 2.3 44 ± 9.44
Tumor size 29.02 ± 3.2 16.02 ± 1.08 9.31 ± 1.42 28.7 ± 2.14
Blood Sugar (100-145mg/dl) 156 ± 7.7 154.2 ± 10.2 215 ± 23.20 118 ± 21.43
Na (135–145mmol/L) 143.2 ± 1.99 143.1 ± 1.15 152.7 ± 5.2 141 ± 3.44
K (3.5–5.5 mmol/L) 3.9 ± 0.36 3.9 ± 0.13 3.7 ± 0.3 3.45 ± 0.32
Urea (14-43 mg/dl) 43.91 ± 6.7 41.6 ± 3.7 45.60 ± 8.5 32.15 ± 3.6
WBC (4–10*1000/mm3) 9.4 ± 0.5 8.01 ± 0.41 10.4 ± 0.7 9.2 ± 0.3
Prolactin
Men: 87–392 mIU/L 309.1 ± 100 719 ± 41 227 ± 23 38,920 ± 20
Women
productive age: 132–498 mIU/L
Post menopause: 90–392 mIU/L
701.5 ± 25 945 ± 52 325 ± 42 44,684 ± 15
Growth Hormone
Women:0.126–9.88 ng/ml 0.2 ± 0.05 12.03 ± 3.25 0.1 ± 0.01 0.06 ± 0.03
Men:0.03–2.47 ng/ml 0.25 ± 0.03 7.62 ± 1.4 0.32 ± 0.04 0.15 ± 0.02
ACTH (7.2–63.3 pg/ml) 24.15 ± 6 41.47 ± 6.13 192.7 ± 52.14 29.7 ± 11
Cortisol (morning)6.2–19.4 μg/dl 11.22 ± 3.77 20.11 ± 4.5 34.43 ± 8.2 7.22 ± 1.2
Testosterone
Men:2.5–10 ng/ml 2.3 ± 1.7 1.02 ± 0.06 1.4 ± 1.02 1.2 ± 0.2
women:0.2–0.95 ng/ml 0.23 ± 0.05 0.24 ± 0.16 0.09 ± 0.5 0.11 ± 0.6
IGF-1
53-234 ng/ml
172.8 ± 22.4 662.9 ± 52.14 236 ± 22 95.4 ± 3.4
















Age (Years) 20–40 34(47.88%) 13(43.33%) 21(51.21%) 10(50%) 7(53.84%) 4(50%)
40–60 22(30.98%) 9(30%) 13(31.70%) 6(30%) 5(38.46%) 2(25%)
60≤ 15(21.12%) 8(26.66%) 7(17.07%) 4(20%) 1(7.69%) 2(25%)
Gender Female 34(47.88%) 12(40%) 22(53.65%) 11(55%) 8(61.53%) 3(37.5%)
Male 37(52.11%) 18(60%) 19(46.34%) 9(45%) 5(38.46%) 5(62.5%)
Tumor
invasiveness
Invasive 33(46.47%) 13(43.33%) 20(48.78%) 10(50%) 4(30.76%) 6(75%)
Non- Invasive 38(53.52%) 17(56.66%) 21(51.21%) 10(50%) 9(69.23%) 2(25%)
Tumor size Micro-
Adenoma
16(22.53%) 0 16(39.02%) 8(40%) 8(61.53%) 0
Macro-
Adenoma
55(77.46%) 30(100%) 25(60.97%) 12(60%) 5(38.46%) 8(100%)
Akbari et al. BMC Endocrine Disorders           (2020) 20:39 Page 3 of 12
pituitary tissues using an enzyme immunoassay kit (Cay-
man Chemicals, USA) in terms of the manufacturer’s
protocol. The kit sensitivity was 15 pg/ml and the wave-
length of 405 nm was applied for the absorbance detection
using microplate reader.
Statistical analysis
In order to analyze the gene expression levels, the com-
parative CT (2-ΔCt) method was applied. The In-
dependant t-test was used to analyse the differences of
COX mRNA expression and PEG2 level between the main
groups. In-dependant t-test compares the mean between
two unrelated groups on the same variable. Also, the one-
way analysis of variance (ANOVA) was used to determine
the statistically significant differences between the means
of more than two unrelated groups; for example, COX-1
expression between functional pituitary adenoma sub-
types. To delineate the possible correlations among pa-
tient’s clinic pathological features and the assayed factors,
the Pearson correlation coefficient test was applied to in-
dicate the possible relationship and association between
variables (Tables 4, 5). The diagnostic values of COX-1,
COX-2 and PEG2 were assessed using the receiver operat-
ing characteristic (ROC) curves. The statistical calcula-
tions were calculated using the Graph Pad Prism version 6
(Graph Pad Software, San Diego California) and Statistical
Package for Social Science (SPSS v.20) with consideration
of p-values < 0.05 to clarify the significant difference be-
tween tested groups.
Results
The COX-1 expression level enhanced in tumor tissues of
different pituitary adenomas
In order to determine the COX-1 expression status in pi-
tuitary adenomas, the COX-1 gene expression level was
measured in 91 pituitary tissues including 71 pituitary ad-
enoma tumor and 20 normal pituitary tissues using Real-
Time PCR. Based on the obtained data, the COX-1 ex-
pression level was elevated in tumor tissues compared to
normal pituitary tissue (P = 0.04) (Fig. 1a). Following the
analysis, the mean and the standard error mean (SEM) of
COX-1 mRNA level were 0.59 ± 0.02 and 0.33 ± 0.04 in
patients and control group, respectively, which were cal-
culated via 2-ΔCt method. Accordingly, the approximately
1.78 fold increase in the level of COX-1 was observed in
tumor tissues compared with healthy pituitary tissue.
Moreover, to address the status of COX-1 expression level
in different types of pituitary adenomas, the tumor tissues
of FPA and NFPA were included in the study and it has
been shown that COX-1 expression level increased in
both FPA and NFPA compared with normal pituitary tis-
sue; however, no significant difference was observed be-
tween FPA and NFPA groups (Fig. 1b). Accordingly, the
mean and the SEM of COX-1 mRNA level were 0.65 ±
0.042, 0.55 ± 0.03, and 0.33 ± 0.04 in NFPAs, FPAs, and
normal tissues, respectively. Also, the approximate 1.96
and 1.66 fold increase were observed in the COX-1 ex-
pression level in NFPAs and FPAs compared to normal
tissues, respectively. Among the prevalent types of FPAs,
it was observed that higher level of COX-1 was expressed
in tumor tissues of acromegaly (0.61 ± 0.048), Cushing
(0.49 ± 0.067), and prolactinoma (0.50 ± 0.037) groups
compared with normal tissue; however, the differences be-
tween FPAs group were not remarkable (Fig. 1c). Also, the
approximate 1.84, 1.48, and 1.51 fold increase were ob-
served in the COX-1 expression levels in acromegaly,
Table 3 Primers used for qRT-PCR assessment of gene
expressions
Gene Primers Primer sequence Tm
Cox-1 Forward 5-GGTAACTGCTTAGGACCAGT-3 58
Reverse 5-ACTGTTCTCCGTACCTTCAC-3
Cox-2 Forward 5-TGTCATTCCAGAGTGCTGAG-3 58
Reverse 5-GGCTAACAAGGAGTTCAGCA-3
Beta-Actin Forward 5-GAT CTC CTT CTG CAT CCT GT-3′ 57
Reverse 5′-TGG GCA TCC ACG AAA CTA C- 3’










Age (Years) 20–40 0.8 0.86 0.86 0
40–60 0.92 0.78 0.62
60≤
Gender Female 0.18 0.35 0.05 0.73
Male
Tumor invasiveness Invasive 0.19 0.54 0.18 0
Non- Invasive
Tumor size Micro-Adenoma 0 0.62 0.65 0
Macro-adenoma
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Cushing, and prolactinoma comparing to normal tissues,
respectively. Tumor size and invasiveness are accounted
as sever features of tumors in pituitary adenomas; there-
fore, these two characters were included in the analysis.
As shown in Tables 1, 22.53% of pituitary tumors in our
study were categorized as microadenomas and 77.46%
were macroadenomas. Based on the data, no significant
difference was observed regarding the expression levels of
COX-1 in macro- and micro-adenomas (Fig. 1d). Add-
itionally, 46.47% of tumors included in the study were in-
vasive and 53.52% of them were non-invasive (Table 1),
which as a point of COX-1 expression, invasive tumors
(0.65 ± 0.035) expressed higher level of COX-1 compared
with the non-invasive tumors (0.50 ± 0.045), (P = 0.015)
and this revealed the approximate 1.3 fold increase (Fig.
1e). The correlation of patients’ clinic pathological features
with COX-1 expression level was evaluated, and despite
the significant correlation of COX-1 with gender in Cush-
ing patients, no significant correlation was observed be-
tween the patients’ features and COX-1expression, which
is summarized in Table 4.
COX-2 revealed higher level of expression in tumor
tissues of different pituitary adenomas comparing to
healthy pituitary tissues
Multiple lines of evidence demonstrated the involvement
of inducible isoform of cyclooxygenase (COX-2) in
tumor genesis although, its status in pituitary adenoma
pathogenesis has yet to be determined [4]. Accordingly,
the COX-2 gene expression was assessed in different
types of pituitary adenomas. As it is reveled in Fig. 2a pi-
tuitary tumor tissues expressed higher level of COX-2
compared to normal pituitary tissue (P = 0.0001) with
the mean and the standard error mean (SEM) of
0.4651 ± 0.02 and 0.1034 ± 0.01 for patients and control
groups, respectively. The analysis which were calculated
by 2-ΔCt method revealing the approximately 4.4 fold in-
crease in the level of COX-2 in tumor tissues compared
to healthy pituitary. Based on the obtained data, the ex-
pression level of COX-2 was significantly elevated in
NFPAs compared with FPAs (P = 0.001). The elevated
level of COX-2 in both FPA and NFPA groups com-
pared with normal pituitary were detected (Fig. 2b). Ac-
cordingly, the mean and the SEM of COX-2 mRNA
level were 0.66 ± 0.04, 0.365 ± 0.027, and 0.1034 ± 0.01 in
NFPAs, FPAs, and normal tissues, respectively. Also, the
approximate 6.6 and 3.6 fold increase were observed in
the COX-2 expression level in NFPAs and FPAs com-
pared to normal tissues, respectively Among the FPAs,
tumor tissues of the patients with acromegaly (0.41 ±
0.039) revealed higher level of COX-2 compared to
Cushing (0.31 ± 0.053) and prolactinoma (0.26 ± 0.039)
patients; however, the observed differences were not sta-
tistically significant between groups Also, the approxi-
mate 4.1, 3.1, and 2.6 fold increase were observed in the
COX-2 expression levels in acromegaly, Cushing, and
prolactinoma comparing to normal tissues, respectively
(Fig. 2c), interestingly, the macroadeomas tumor tissues
(0.52 ± 0.036) expressed more COX-2 compared to
microadenomas (0.30 ± 0.043) (P = 0.01) and this re-
vealed the approximate 1.73 fold increase (Fig. 2d). Add-
itionally, in terms of invasive tumors the expression level
of COX-2 was significantly increased compared to the
non-invasive tumors (P = 0.04) which were (0.52 ± 0.042)
and (0.40 ± 0.039), respectively. (Fig. 2e). It indicated the
approximate 1.3 fold increase in the COX-2 expression
level in invasive and non-invasive pituitary adenomas.
Regarding the correlation of patient’s clinic pathological
features with COX-2 expression which is summarized in
Table 5, the COX-2 expression seemed to be correlated
with gender in Cushing and prolactinoma, although it
was not observed for the other types of pituitary aden-
omas. In addition, the tumor invasiveness was correlated
with COX-2 expression in NFPAs which was not ob-
served for the other groups.
The elevation of PGE2 in pituitary adenomas
The PGE2 exert positive role in cell proliferation, angio-
genesis and inflammation, and its synthesis is tightly in-
fluenced by COX isoforms [28]. The assessment of this










Age (Years) 20–40 0.88 0.9 0.4 0
40–60 0.56 0.17 0.61
60≤
Gender Female 0.29 0.76 0.04 0.057
Male
Tumor invasiveness Invasive 0.05 0.84 0.21 0
Non- Invasive
Tumor size Micro-Adenoma 0 0.54 0.07 0
Macro-adenoma
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bioactive lipid in tumor and healthy tissues of pituitary
in the current study showed the higher level of PGE2 in
pituitary tumors compared with normal tissue (P =
0.0001) (Fig. 3a). Following the analysis, the mean and
the standard error mean (SEM) of PGE2 level were
80.21 ± 2.3 and 22.32 ± 2.7 in patients and control group,
respectively, which indicates the 3.59 fold increase in the
level of PGE2 patients compared to the healthy individ-
uals. Notably, the PGE2 level was significantly increased
in NFPAs (84.61 ± 3.7) compared to FPAs (75.38 ± 2.4)
(P = 0. 04) (Fig. 3b). Also, the approximate 3.7 and 3.3
fold increase were observed in the PGE2 level in NFPAs
and FPAs compared to normal group, respectively.
Among the FPAs, the level of PGE2 enhanced in all
types of pituitary tumors (Acromegaly (81.68 ± 3.6),
Cushing (72.81 ± 24.3) and Prolactinoma (65.70 ± 1.3)
compared to the healthy group; however; no remarkable
difference was observed between FPAs subtypes (Fig.
3c). Also, the approximate 3.65, 3.26, and 2.9 fold in-
crease were observed in the PGE2 levels in acromegaly,
Cushing, and prolactinoma comparing to normal group,
respectively The higher level of PGE2 in macroadenoma
(82.79 ± 2.7) tumor tissues was observed compared to
the microadenoma tissues (71.59 ± 3.2) indicating the
Fig. 1 COX-1 expression level in pituitary adenomas. The expression level of COX-1 was evaluated in tumor and normal tissues of pituitary with
different adenoma types. The COX-1 expression level was increased in pituitary adenoma (a), non-functional pituitary adenoma (b), functional
pituitary adenoma subtypes (c), macroadenoma (d) and invasive (e) tumor tissues. The Statistical differences between groups is shown as asterisk
(* = P < 0.05, ** = P < 0.01)
Akbari et al. BMC Endocrine Disorders           (2020) 20:39 Page 6 of 12
1.15 fold increase (P = 0.04) (Fig. 3d), also, the level of
PGE2 was elevated in invasive tumors (88.60 ± 3.9) com-
pared to non-invasive tumors (73.11 ± 2.1) revealing the
1.21 fold increase (P = 0.001) (Fig. 3e).
The diagnostic value of COX isoforms and PGE2 in
pituitary adenomas
The diagnostic value of the COX-1, COX-2 and PGE2
were evaluated between examined groups using ROC
curves. The diagnostic values are indicated by area under
the curve (AUC) and the cutoff value for each param-
eter. As it is indicated in Fig. 4a, the COX-1 expression
between pituitary tumor and normal tissue group
showed the AUC level of 0.827 (95% CI, 0.723–0.931,
P = 0.0001) and 0.43 as cut off value with 76% sensitivity
and 75% specificity based on Youden Index. However;
the AUC level of 0.618 (95% CI, 0.468–0.769, P = 0.128)
and the cut of value of 0.51 (70% sensitivity and 50%
specificity) was determined for COX-1 expression diag-
nostic value between NFPAs and FPAs (Fig. 4b). Not-
ably, the COX-2 gene expression between pituitary
tumor and normal tissue group showed the AUC level
of 0.964 (95% CI, 0.926–1, P = 0.0001) and 0.18 as cut
off with 90% sensitivity and specificity (Fig. 4c) while its
expression between NFPAs and FPAs group showed the
AUC level of 0.856 (95% CI, 0.763–0.949, P = 0.0001)
Fig. 2 COX-2 expression level in pituitary adenomas. The expression level of COX-2 was evaluated in tumor and normal tissues of pituitary with
different adenoma types. The COX-2 expression level was increased in pituitary adenoma (a), non-functional pituitary adenoma (b), functional
pituitary adenoma subtypes (c), macroadenoma (d) and invasive (e) tumor tissues. The Statistical differences between groups is shown as asterisk
(* = P < 0.05, ** = P < 0.01,*** = P < 0.001)
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and cut off value of 0.42 (86% sensitivity, 71% specificity)
(Fig. 4d). The PGE2 revealed the diagnostic value be-
tween pituitary tumor and normal tissue group as the
AUC level of 0.996 (95% CI, 0.987–1, P = 0.0001) and
cut off value of 49.8 with 100% sensitivity and specificity
(Fig. 4e). However; the AUC level of 0.628 (95% CI,
0.487–0.769, P = 0.087) and cut off value of 77.8 (50%
sensitivity and 48.9% specificity) was determined for
PGE2 level between NFPAs and FPAs group (Fig. 4f).
Based on the results, the COX isoforms and PGE2 level
can significantly distinguish pituitary tumors versus
pituitary normal tissues, however; the COX-2 level
showed better diagnostic value between NFPAs and
FPAs group.
Discussion
Pituitary adenomas account for approximately 15% of
intracranial neoplasms and impose a devastating burden
of morbidity on patients, which arises from the multi-
functional role of the pituitary gland in the body [29].
These heterogeneous types of tumors might be endocri-
nologically active or in-active, the underlying molecular
Fig. 3 PGE2 level in pituitary adenomas. The level of PGE2 was evaluated in tumor and normal tissues of pituitary with different adenoma types.
The PGE2 level was increased in pituitary adenoma (a), non-functional pituitary adenoma (b), functional pituitary adenoma subtypes (c),
macroadenoma (d) and invasive (e) tumor tissues. The Statistical differences between groups is shown as asterisk (* = P < 0.05,
** = P < 0.01, *** = P < 0.001)
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mechanism involving tumor pathogenesis has yet to be
characterized. The COX pathway holds great promise as
an effective cellular pathway for triggering tumor initi-
ation, progression and apoptosis, and multiple bodies of
evidences suggest the over-expression of COX isoforms
in several types of tumors, including breast, pancreatic,
lung, colorectal, leukemia, lymphoma, renal cell carcin-
oma and head and neck cancers [4, 22, 23]. Selective
COX inhibitors are able to manipulate the fate of cancer
cells as well as cell proliferation, invasion, angiogenesis,
death and the immune system response, which together
reinforce the impact of the COX pathway in cancer
pathogenesis [7]. Due to a lack of data regarding the sta-
tus of COX isoforms in pituitary adenomas, the expres-
sion profile of COX isoforms and PGE2 were perused in
the current study. The higher expression levels of both
COX isoforms were observed in pituitary adenomas
compared with normal pituitary tissue; however, the fold
change in COX-2 expression level was higher than that
of COX-1 in tumors compared with healthy tissue. No
similar studies were found to have evaluated the status
of COX-1 expression in human pituitary adenoma; how-
ever, an elevated level of COX-2 expression was reported
in pituitary carcinomas and oncocytic and non-
Fig. 4 COX-1, COX-2 and PGE2 ROC curve. The COX-1, COX-2 and PGE2 ROC Curve, area under the curve, 95% confidence interval, P value are
shown for COX-1 in pituitary patients /healthy tissues (a), COX-1 in NFPAs/FPAs (b), COX-2 in pituitary patients /healthy tissues (c), COX-2 in
NFPAs/FPAs (d), PGE2 in pituitary patients /healthy tissues (e), PGE2 in NFPAs/FPAs (f)
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oncocytic null-cell adenomas, although the methodology
of that study differed from that of the current study [30,
31]. Onguru et al., measured the protein level of COX-2
by immunohistochemistry, while the current study,
assessed the mRNA levels of both COX isoforms, and, in
order to delineate whether COX mRNA expression con-
veys protein expression, assessed the level of PGE2 as an
active product of the COX-2 enzyme. The consistency of
PGE2 over- production with COX-2 over- expression
emphasized the existence of active COX-2 proteins and
enzymes in pituitary tumors. The up-regulation of the
COX-1 enzyme was detected in some types of tumors,
including renal cell carcinoma and head and neck can-
cers, and the current data indicates a pro-tumor genesis
effect of COX-1 in pituitary adenomas. The coordinate
expression pattern of COX-1 and COX-2 in pituitary ad-
enomas in the current study indicates the propelling role
of both isoforms in pituitary adenoma pathogenesis, al-
though COX-2 distinguished tumors tissues from
healthy pituitary tissues more accurately and signifi-
cantly compared with COX-1. Additionally, COX-1 ex-
pression levels were enhanced in invasive tumors, while
no significant differences were observed among different
types of pituitary tumors or in micro-and macro-
adenomas. Based on the data in the current study, COX-
2 levels were significantly higher in NFPAs than in FPAs
with a significant diagnostic value for distinguishing
these two groups. In support of this, Sokołowski et al.,
revealed that COX-2 was more expressed in non-
secreting hormone pituitary adenomas, while prolacti-
noma patients showed the lowest expression levels of
the COX-2 enzyme [32]. In the current study, no differ-
ence among the FPAs subtypes as a point of COX-2 ex-
pression was observed, although acromegaly tumor
tissue and prolactinoma revealed the highest and lowest
levels of COX-2 in endocrinologically active pituitary tu-
mors, respectively. This result is in line with previously
reported evidence [31, 32]. Apparently, the observed
level of COX-2 expression might be affected by the
number of acromegaly and prolactinoma participants in
the current study, which should be refined by further
studies. Interestingly, the up-regulation of COX-2 was
accompanied by STAT3 phosphorylation and facilitation
of epithelial-mesenchymal transition (EMT), which re-
sulted in osteosarcoma metastasis and invasion [33].
Moreover, inhibition of COX-2 caused attenuated mi-
gration and invasion of radiation-resistant lung cancer
cells through the involvement of specificity protein 1
(Sp1) [34]. Notably, COX-2 induced HIF2α level and ac-
tivity and HIF2α nuclear translocation through the
MAPK pathway, which consequently enhanced angio-
genesis and proliferative mediators in hepatocellular car-
cinoma [35]. In support of this, the overexpression of
COX-2 in invasive pituitary tumors and macroadenomas
in the current study might emphasize the accelerating
role of COX-2 in inducing higher rates of cell prolifera-
tion in pituitary adenomas. The mechanism by which
COX-2 mediates pituitary adenoma invasion cannot be
concluded from the current results, and further mechan-
istic studies are required to characterize the exact role of
COX-2 in this regard. PGE2 accounts as the main prod-
uct of COX-2 is involved in various cellular functions in-
cluding cancer cell proliferation, invasion, and death
through the activation of EP receptors and subsequent
induction of cAMP and protein kinase K [16]. PGE2
might affect cancer pathogenesis by different mecha-
nisms. For example, it has been reported that PGE2 me-
diates Src kinase activation and STAT3 phosphorylation
in lung cancer [18]. Notably, it has been revealed that
PGE2 enhanced growth hormone release in bovine an-
terior pituitary cells in-vitro [36]. Based on data from
the current study, PGE2 expression was elevated re-
markably in pituitary tumors compared with normal tis-
sues. Moreover, an increased level of PGE2 was
observed in NFPAs, invasive tumors and macro aden-
omas indicating the presumable role of PGE2 in pituit-
ary tumor invasion and tumor genesis although this
premise should be clarified by further studies. The sim-
ultaneous elevation of COX-2 and PGE2 in relatively
similar patterns in pituitary tumors reinforces the in-
sights regarding the consistency of COX-2 mRNA and
protein in pituitary adenomas. The current study re-
vealed no significant correlation between COX isoforms
or PGE2 levels and patient’s age, gender, or tumor size
which can be characterized by more populated studies
although no correlation with patient’s age, tumor size, or
invasiveness was observed in previous studies [31]. Not-
ably, a large number of non-secreting pituitary adenomas
that can be clinically diagnosed have macroadenoma and
quite heterogenic tumors which cause pituitary insuffi-
ciency and complicate diagnosis and treatment [26]. Ra-
tionally, the presence of larger tumors in patients with
NFPAs might be due to the accelerated cell proliferation
and reduced cell apoptosis which facilitate tumor growth
and invasion. In support of this, the apoptotic index was
shown to be remarkably lower in NFPAs compared with
FPAs. Moreover, the reduced level of p27 KIP1, the cyclin-
dependent kinase inhibitor which suppresses the cell cycle,
was observed more in NFPAs and pituitary carcinomas
[37–39]. Based on the current data, higher expression
levels of COX-2 isoforms and PGE2 were observed re-
markably more in NFPAs compared with other types of
pituitary tumors. In the case of COX-2, these elevated
levels were correlated with tumor invasion. Due to the
multiple lines of evidences COX-2 and PGE2 have accel-
erating role in cell proliferation and invasion [4] in
addition NFPAs have higher rates of cell proliferation
compared with other pituitary adenomas. Therefore, the
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up-regulation of COX-2 and PGE2 in the current study
might be due to the stimulatory role of COX-2 in cell pro-
liferation in NFPAs. Based on the fact that tumor mass is
a heterogeneous population of cells, a question might be
raised about the types of cells in pituitary tumors, which
causes the over-production of COX pathway mediators.
However, the current study evaluated equal amounts of
tumor mass from different pituitary tumors and compared
them so as to uncover the existence and patterns of COX
isoforms expression. The type of cell that might be in-
volved in COX isoform expression cannot be determined
from the current study and should be taken in to consid-
eration in future studies. Because of the pro-tumor genesis
role of COX isoforms and PGE2 in several tumor types,
the results of the current study provide new insight into
the probable effect of the COX pathway in pituitary aden-
omas and its potential ability to be considered as an effect-
ive target in pituitary adenoma diagnosis. However, to
reach a solid conclusion, evaluating the COX isoforms
protein levels, enzyme activity, and the roles of other pros-
taglandins seems to be a prerequisite to delineate the bal-
ance between different mediators of the pathway.
Conclusions
The current study is the first to provide data regarding
the evaluation of the main COX pathway enzymes
(COX-1 and COX-2) and product (PGE2) in relatively
most prevalent types of pituitary adenomas, including
hormone-secreting and non-secreting tumors. Accord-
ingly, the over-expression of both enzyme isoforms was
observed in tumor tissue and was more significant for
COX-2 and consistent with PGE2 elevation. Among pi-
tuitary tumors, non-secreting ones revealed more ex-
pression of COX isoforms, possibly because of the
higher rate of cellular proliferation in such tumors.
Overall, the expression levels of COX isoforms and
PGE2 levels were increased in various types of pituitary
adenomas and can be considered as possible diagnostic
biomarkers, especially for invasive pituitary adenomas in
future surveys.
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